Schistosomiasis vaccine development: update on human clinical trials

Area of Science:

• Tropical Medicine
• Parasitology
• Vaccinology

Background:

• Schistosomiasis is a major global health concern causing significant morbidity and mortality.
• Current control relies on mass drug administration (MDA) with praziquantel (PZQ), the sole available treatment.
• PZQ has limitations including ineffectiveness against juvenile parasites, lack of re-infection prevention, and emerging resistance.

Purpose of the Study:

• To review the current status of schistosomiasis vaccine candidates in clinical trials.
• To provide insights into future vaccine discovery and design for schistosomiasis elimination.

Main Methods:

• Literature review of schistosomiasis vaccine candidates.
• Analysis of clinical trial data for vaccine efficacy and safety.
• Exploration of future directions in vaccine development.

Main Results:

• Existing control measures like MDA and sanitation programs have proven insufficient to interrupt schistosomiasis transmission.
• No effective schistosomiasis vaccine is currently available, highlighting a critical gap in control strategies.
• Several vaccine candidates are in various stages of human clinical trials, showing promise for future control.

Conclusions:

• Integrated control strategies, combining vaccines with MDA and other interventions, are essential for schistosomiasis elimination.
• Vaccine development is crucial for long-term protection and overcoming the limitations of current drug-based approaches.
• Further research into vaccine design and clinical evaluation is needed to achieve global schistosomiasis eradication.